Pattern Recognition Receptor Agonist Development Service for Cancer Immunotherapy

The Urgent of Pattern Recognition Receptor Agonist Development

Pattern recognition receptors (PRRs) are essential molecules in initiating and sustaining innate immunity, particularly in the regulation of immune cells within the tumor environment. They directly facilitate both the promotion and suppression of cancer cells. PRR agonists hold significant potential in cancer treatment, offering a vast scope for clinical research. As a result, there is an urgent need to develop more PRR agonists to boost cancer immunotherapy.

Fig.1 Activation of PRR agonist causes alterations in dormant infected cells or neighboring components.¹

Our Pattern Recognition Receptor Agonist Development Service for Cancer Immunotherapy

Creative Biolabs' pattern recognition receptor agonist development service for cancer immunotherapy takes advantage of genetic engineering technology to generate recombinant protein, which is used to mimic the binding of natural ligands to PRRs. In our service, we provide agonist developing service targeting customers' desirable PRRs. Simultaneously, we also supply customized solutions for your PRR agonist development projects. By the way, we deliver several hot markers to facilitate your PRR agonist development accurately. In addition, the appropriate animal models are crucial for investigating the mechanism and biological effects of PRR agonists. We not only deliver a series of ready-to-use humanized animal models but also deliver customized animal model construction services, aiding in your demands to screen safe and effective PRR agonists. We encourage global customers to inquire and place orders.

Promising PRR Targets at Creative Biolabs

Here are several PRRs that are associated with specific cancers. Customers could choose the desirable PPRs to develop specialized agonists.

PRRs	Associated Cancers
TLR2	Squamous cell NSCLC
TLR3	HCC, glioblastoma
TLR4	NSCLC, melanoma, follicular lymphoma
TLR7	Breast cancer cutaneous metastases
TLR8	HPV+ squamous cell carcinoma of the head and neck, breast cancer cutaneous metastases
TLR9	Melanoma, NSCLC, B-cell and T-cell lymphomas, pancreatic ductal adenocarcinoma
NOD-2	Non-metastatic osteosarcoma
NLRP3	NSCLC, melanoma
Dectin-1	NSCLC, melanoma, breast cancer, indolent non-hodgkin lymphoma, colorectal cancer
RIG-I	Advanced tumors, advanced solid tumors
STING	Lymphoma, advanced solid tumors, head and neck cancer, melanoma

Animal Models Available at Creative Biolabs

Animal models play a crucial role in the efficacy and safety verification of developed PRR agonists. We provide multiple types of animal models for precisely screening PRR agonists:

Transgenic Animal Model: The model constructed by transferring specific human PRR genes into animals by genetic engineering technology can be used to study the biological effects of human PRR agonists in animals and evaluate the therapeutic efficacy and safety of agonists.
Gene Knockout Animal Model: The model constructed by knocking out a specific PRR gene in an animal can be used to study the effect of PRR agonists on animals lacking that PRR gene.
Tumor Animal Model: The model constructed by injecting tumor cells into animals can be used to evaluate the effect of PRR agonists on tumor growth and tumor immune response, and to explore the efficacy and mechanism of PRR agonists in tumor treatment.
Infection Animal Model: The model constructed by using pathogen-infected animals can be used to study the anti-infection and immunomodulatory effects of PRR agonists.

PRR Agonist Broadly Applied in Cancer Immunotherapy

Single-drug therapy: Directly activating PRRs on the surface of tumor cells.
Group with other therapies or vaccines: Combination with therapeutic vaccines, checkpoint inhibitors, and broad neutralizing antibodies.

If you want to know more about our pattern recognition receptor agonist development service for cancer immunotherapy, please feel free to contact us. Anticipating your inquiry and order.

Reference

Takahama, Shokichi, and Takuya Yamamoto. "Pattern recognition receptor ligands as an emerging therapeutic agent for latent HIV-1 infection." Frontiers in Cellular and Infection Microbiology 10 (2020): 216.

For Research Use Only | Not For Clinical Use